Abstract
Objective
Coronavirus disease 2019 (COVID-19) is often accompanied by gastrointestinal symptoms, which are related to gut microbiota dysbiosis (GMD). Whether washed microbiota transplantation (WMT) is an effective treatment for COVID-19 patients suspected of having GMD by restoring the gut microbiota is unknown. This study is designed to explore the efficacy and safety of WMT in COVID-19 patients suspected of having GMD.
Methods
This is a randomized, multicenter, single-blind prospective study. COVID-19 patients suspected of having GMD will be randomly divided to receive routine treatment only or to receive routine treatment and WMT. The frequency of WMT will be once a day for three consecutive days. Laboratory and imaging examinations will be performed at admission, 1 and 2 weeks after treatment, and on the day of discharge. Then a telephone follow-up will be conducted at 1st week, 2nd week, and 6th month after discharge. The clinical efficacy and safety of WMT in COVD-19 patients suspected of having GMD and the effects of WMT on the organ function, homeostasis, inflammatory response, intestinal mucosal barrier function, and immunity of the patients will be evaluated.
Results
By following the proposed protocol, WMT is expected to be efficacious and safe for the treatment of COVID-19 patients suspected of having GMD, and the therapeutic effect is expected to be associated with improvement of the intestinal mucosal barrier function, inflammatory response, and immunity.
Conclusion
The findings from this study may offer a new approach for the prevention and treatment of COVID-19 patients suspected of having GMD.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Sun P, Lu X, Xu C, et al. Understanding of COVID-19 based on current evidence. J Med Virol, 2020,92(6):548–551
Cheung KS, Hung IFN, Chan PPY, et al. Gastrointestinal manifestations of SARS-CoV-2 infection and virus load in fecal samples from a Hong Kong cohort: Systematic review and meta-analysis. Gastroenterology, 2020,159(1):81–95
Zuo T, Zhang F, Lui GCY, et al. Alterations in gut microbiota of patients with COVID-19 during time of hospitalization. Gastroenterology, 2020,159(3):944–955
Yao WU. Effect of intestinal flora imbalance on acute lung injury in mice infected with influenza virus. Modern Prevent Med (Chinese), 2018,45(4):694–699
Tay MZ, Poh CM, Rénia L, et al. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol, 2020,20(6):363–374
Bradley KC, Finsterbusch K, Schnepf D, et al. Microbiota-driven tonic interferon signals in lung stromal cells protect from influenza virus infection. Cell Rep, 2019,28(1):245–256.e244
Yitbarek A, Taha-Abdelaziz K, Hodgins DC, et al. Gut microbiota-mediated protection against influenza virus subtype H9N2 in chickens is associated with modulation of the innate responses. Sci Rep, 2018,8(1):13189
Lee PH, Tay WC, Sutjipto S, et al. Associations of viral ribonucleic acid (RNA) shedding patterns with clinical illness and immune responses in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection. Clin Transl Immunology, 2020,9(7):e1160
d’Ettorre G, Ceccarelli G, Marazzato M, et al. Challenges in the management of SARS-CoV2 infection: The role of oral bacteriotherapy as complementary therapeutic strategy to avoid the progression of COVID-19. Front Med (Lausanne), 2020,7:389
Zhang T, Lu G, Zhao Z, et al. Washed microbiota transplantation vs. manual fecal microbiota transplantation: clinical findings, animal studies and in vitro screening. Protein Cell, 2020,11(4):251–266
Nanjing consensus on methodology of washed microbiota transplantation. Chin Med J (Engl), 2020,133(19):2330–2332
National Health Commission of the People’s Republic of China. COVID-19 diagnosis and treatment guideline in china, 7th ed. http://www.nhc.gov.cn/yzygj/s7653p/202003/46c9294a7dfe4cef80dc7f5912eb1989.shtml.
Lim WS, van der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax, 2003,58(5):377–382
Knaus WA, Draper EA, Wagner DP, et al. APACHE II: a severity of disease classification system. Crit Care Med, 1985,13(10):818–829
Ianiro G, Mullish BH, Kelly CR, et al. Screening of faecal microbiota transplant donors during the COVID-19 outbreak: suggestions for urgent updates from an international expert panel. Lancet Gastroenterol Hepatol, 2020,5(5):430–432
Matsumoto H, Shiotani A, Graham DY. Current and future treatment of Helicobacter pylori infections. Adv Exp Med Biol, 2019,1149:211–225
Thursby E, Juge N. Introduction to the human gut microbiota. Biochem J, 2017,474(11):1823–1836
Choi HH, Cho YS. Fecal microbiota transplantation: Current applications, effectiveness, and future perspectives. Clin Endosc, 2016,49(3):257–265
Li H, Liu X, Chen F, et al. Avian influenza virus subtype H9N2 affects intestinal microbiota, barrier structure injury, and inflammatory intestinal disease in the chicken ileum. Viruses, 2018,10(5):270
Hanada S, Pirzadeh M, Carver KY, et al. Respiratory viral infection-induced microbiome alterations and secondary bacterial pneumonia. Front Immunol, 2018,9: 2640
Yildiz S, Mazel-Sanchez B, Kandasamy M, et al. Influenza A virus infection impacts systemic microbiota dynamics and causes quantitative enteric dysbiosis. Microbiome, 2018,6(1):9
Oldstone MB, Rosen H. Cytokine storm plays a direct role in the morbidity and mortality from influenza virus infection and is chemically treatable with a single sphingosine-1-phosphate agonist molecule. Curr Top Microbiol Immunol, 2014,378:129–147
Wang S, Le TQ, Kurihara N, et al. Influenza virus-cytokine-protease cycle in the pathogenesis of vascular hyperpermeability in severe influenza. J Infect Dis, 2010, 202(7):991–1001
Marcella C, Cui B, Kelly CR, et al. Systematic review: the global incidence of faecal microbiota transplantation-related adverse events from 2000 to 2020. Aliment Pharmacol Ther, 2021,53(1):33–42
Ye ZN, Xia HH, Zhang R, et al. The efficacy of washed microbiota transplantation on Helicobacter pylori eradication: A pilot study. Gastroenterol Res Pract, 2020, 2020:8825189
Zhong HJ, Zeng HL, Cai YL, et al. Washed microbiota transplantation lowers blood pressure in patients with hypertension. Front Cell Infect Microbiol, 2021,11: 679624
Wang S, Xu M, Wang W, et al. Systematic review: Adverse events of fecal microbiota transplantation. PloS one. 2016,11(8):e0161174
He XX, Wu LH, Ye ZN, et al. Treatment of COVID-19 patients suspected with gut microbiota dysbiosis with washed microbiota transplantation: study protocol for a randomized controlled trial. Preprint at https://www.researchsquare.com/article/rs-56663/v1 (2020).
Acknowledgments
We thank Dr. Tao LIU for his help with the Statistical Analysis section of this article.
Author information
Authors and Affiliations
Corresponding author
Additional information
Conflict of Interest Statement
All authors have no conflict of interest in this study.
This study was supported by the Special Research Project on Prevention and Control of COVID-19 in Universities of the Guangdong Provincial Education Department (No. 2020KZDZX1132).
Electronic Supplementary Material
Rights and permissions
About this article
Cite this article
Wu, Lh., Ye, Zn., Peng, P. et al. Efficacy and Safety of Washed Microbiota Transplantation to Treat Patients with Mild-to-Severe COVID-19 and Suspected of Having Gut Microbiota Dysbiosis: Study Protocol for a Randomized Controlled Trial. CURR MED SCI 41, 1087–1095 (2021). https://doi.org/10.1007/s11596-021-2475-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11596-021-2475-2